📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
45 announcements match the current filters (relevance ≥ 5).
GKSL Shareholders Approve Healthcare Expansion Funds and Financial Statement Revision
Gujarat Kidney and Super Speciality Limited (GKSL) has announced the successful passage of three key resolutions via postal ballot with near-unanimous support. Shareholders approved the interim utilization of funds for healthcare expansion, aligning with the company's IPO objectives. Notably, a special resolution for the voluntary revision of financial statements and the Board's report under Section 131 of the Companies Act was also passed. Additionally, the company confirmed the appointment of Mr. Dharmendra Bhaliya as the Secretarial Auditor for the 2025-26 fiscal year.
Key Highlights
Resolution for healthcare expansion fund utilization passed with 100% of 5,68,46,254 valid votes in favor.
Voluntary revision of Financial Statements and Board's Report approved with a 99.9998% majority.
Total voter participation represented 72.10% of the company's total outstanding shares.
Appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 was finalized with 99.9994% approval.
👀 What to Watch
Investors should monitor the specific reasons for the voluntary revision of financial statements to ensure there are no underlying accounting or governance concerns. While the expansion plan is a positive growth indicator, the regulatory revision warrants a cautious approach.
Kalyani Steels CFO Bal Mukand Maheshwari Resigns After 13-Year Tenure
Kalyani Steels Limited has announced the resignation of its Chief Financial Officer (CFO), Mr. Bal Mukand Maheshwari, effective May 8, 2026. Mr. Maheshwari has served as the CFO for the past 13 years and cited personal reasons for his departure. The company has confirmed there are no other material reasons for the resignation. A smooth transition process is expected as the outgoing CFO has committed to extending full cooperation during the handover.
Key Highlights
Mr. Bal Mukand Maheshwari resigns as CFO and Key Managerial Personnel (KMP) after 13 years of service.
The resignation was officially tendered on April 16, 2026, with the relief date set for May 8, 2026.
Departure is attributed to personal reasons with no other material concerns cited.
The company must now identify a successor to lead its financial operations and strategy.
👀 What to Watch
Investors should monitor the company's announcement regarding a successor to ensure a qualified candidate is appointed to maintain financial stability. The long tenure of the outgoing CFO suggests a significant leadership transition that needs to be watched for any changes in financial strategy.
Kalyani Steels Completes Acquisition of 4.85% Stake in Clean Renewable Energy KK 1B
Kalyani Steels Limited (KSL) has successfully completed the acquisition of a 4.85% equity stake in Clean Renewable Energy KK 1B Private Limited, an SPV of Hero Rooftop Energy Private Limited. The company acquired 1,034,453 equity shares at a price of Rs. 28.37 per share, which includes a premium of Rs. 18.37 over the face value of Rs. 10. This strategic move is likely intended to meet captive power requirements or green energy mandates for its manufacturing operations. The transaction follows the initial proposal announced on March 27, 2026.
Key Highlights
Acquisition of 1,034,453 equity shares in Clean Renewable Energy KK 1B Private Limited.
Shares purchased at Rs. 10 face value plus a premium of Rs. 18.37 per share.
The acquired stake represents 4.85% of the total paid-up equity capital of the SPV.
The target entity is a Special Purpose Vehicle (SPV) of Hero Rooftop Energy Private Limited.
👀 What to Watch
Investors should view this as a strategic step towards securing renewable energy, which could optimize long-term power costs and improve ESG ratings. No immediate impact on earnings is expected given the small stake size.
Kalyani Steels to Acquire 4.85% Stake in Clean Renewable Energy for Rs 2.93 Crore
Kalyani Steels Limited (KSL) has announced a strategic investment to acquire a 4.85% equity stake in Clean Renewable Energy KK 1B Private Limited, an SPV of Hero Rooftop Energy. The acquisition involves a cash consideration of Rs 2.93 crore for 1,034,453 equity shares. This move is designed to facilitate the sourcing of power through captive renewable energy sources under the group captive scheme. The target entity is a new venture incorporated in July 2024, specifically focused on electricity generation.
Key Highlights
Acquisition of 1,034,453 equity shares representing a 4.85% stake in the target SPV.
Total cash consideration for the transaction is Rs 2,93,50,000.
Target entity is an SPV of Hero Rooftop Energy Private Limited focused on renewable power generation.
Investment aims to optimize power costs and comply with group captive energy regulations.
The target company was incorporated in July 2024 and reported no turnover for FY 2024-25.
👀 What to Watch
This is a strategic move to secure long-term renewable energy and optimize operational costs. While the investment amount is relatively small, it reflects a positive shift towards sustainable energy sourcing.
GKSL to Reallocate ₹3192.5 Lakhs IPO Funds and Revise Past Financial Statements
Gujarat Kidney And Super Speciality Limited (GKSL) has issued a postal ballot seeking shareholder approval to significantly reallocate IPO proceeds. The company plans to divert ₹2510 lakhs originally intended for a Vadodara hospital toward a new multispeciality project in Bharuch and ₹682.50 lakhs toward a dialysis services collaboration. Furthermore, the company is voluntarily revising its financial statements and Board's reports for FY 2021-22, 2022-23, and 2023-24 following an NCLT order to ensure proper disclosure compliance.
Key Highlights
Reallocation of ₹3010 lakhs from a proposed Vadodara hospital to a new multispeciality hospital project in Bharuch.
Diversion of ₹682.50 lakhs from robotics equipment to establish dialysis services in collaboration with Lord’s Mark Industries Limited.
Voluntary revision of financial statements and notes for three consecutive years (FY22 to FY24) as per NCLT order dated Feb 6, 2026.
Utilization of ₹1262 lakhs from General Corporate Purposes to fund the revised healthcare expansion objects.
Remote e-voting for these resolutions is scheduled from March 27, 2026, to April 25, 2026.
👀 What to Watch
Investors should closely examine the reasons for the geographic shift in expansion and the implications of the voluntary financial revisions on the company's historical performance data. Monitor the progress of the new Bharuch project as it replaces the original IPO objective.
GKSL Q2 FY26 Results: Revenue Up 2.5% to ₹9.64 Cr, PAT Declines 22% YoY
Gujarat Kidney And Super Speciality Limited (GKSL) reported a marginal 2.5% YoY revenue growth for Q2 FY26, reaching ₹9.64 crore. However, Profit After Tax (PAT) for the quarter dropped significantly by 22% to ₹2.30 crore compared to the same period last year, indicating margin pressure. On a half-yearly basis, the performance remains positive with revenue up 13% and PAT up 10% YoY. Investors should note a sharp increase in current borrowings to ₹12.71 crore and rising trade receivables, which may impact liquidity.
Key Highlights
Q2 Revenue from operations stood at ₹964.26 Lacs, a slight increase from ₹941.00 Lacs YoY.
Quarterly Net Profit declined to ₹230.12 Lacs from ₹295.73 Lacs in the previous year's quarter.
Half-year (H1) PAT grew by 10.1% to ₹620.10 Lacs compared to ₹563.13 Lacs in H1 FY25.
Current borrowings escalated sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025.
Trade receivables increased to ₹1,862.59 Lacs as of September 2025, up from ₹1,279.91 Lacs in March 2025.
👀 What to Watch
Investors should exercise caution due to the significant rise in short-term debt and trade receivables, which could signal working capital stress. Monitor the company's ability to manage operational costs as quarterly margins have contracted despite stable revenue.
GKSL Acquires Parekhs Hospital Private Limited for ₹77 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has successfully executed the acquisition of a 100% stake in Parekhs Hospital Private Limited for ₹77 crore. The target entity, based in Ahmedabad, is a healthcare service provider with a steady revenue stream, reporting a turnover of ₹25.67 crore in FY 2024-25. This acquisition makes Parekhs Hospital a wholly-owned subsidiary of GKSL, aimed at strengthening the company's presence in the healthcare sector. The transaction was completed on March 22, 2026, through cash consideration.
Key Highlights
Acquisition of 100% equity (2,55,000 shares) for a total cash consideration of ₹77 crore
Parekhs Hospital reported a turnover of ₹25.67 crore for FY 2024-25, showing stable performance
Target company has a consistent financial track record with FY 2022-23 turnover at ₹24.06 crore
Strategic expansion into the Ahmedabad healthcare market to diversify GKSL's business portfolio
The acquisition was completed on March 22, 2026, following an initial intimation in January 2026
👀 What to Watch
Investors should view this as a significant growth move, though the acquisition price of ₹77 crore for a ₹25.67 crore turnover business implies a high valuation multiple. Monitor the consolidated financial statements for improvements in margins and operational synergies post-integration.
GKSL Pays Rs 6.6 Lakh Penalty to BSE and NSE for Delayed Financial Results
Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges regarding a penalty payment of Rs 3,30,400 each to BSE and NSE, totaling Rs 6,60,800. The fine was imposed due to the company's failure to submit financial results within the prescribed timelines under Regulation 33 of SEBI LODR Regulations. The notices were received on March 17, 2026, and the company completed the payment via RTGS on March 21, 2026. While the monetary impact is limited, the delay in financial reporting is a negative signal regarding corporate governance and compliance discipline.
Key Highlights
Total penalty of Rs 6,60,800 paid to stock exchanges (Rs 3,30,400 each to BSE and NSE).
Penalty triggered by non-compliance with Regulation 33 for delayed submission of financial results.
Notices were issued by the exchanges on March 17, 2026, and received late in the evening.
Company confirmed the full payment of fines was completed on March 21, 2026, via RTGS.
👀 What to Watch
Investors should exercise caution and monitor if the company improves its reporting discipline in future quarters. It is important to review the delayed financial results once published to check for any underlying operational issues.
GKSL Appoints New Auditors; H1 FY26 Revenue Grows to ₹21.09 Cr, PAT at ₹6.20 Cr
Gujarat Kidney And Super Speciality Limited (GKSL) has appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26 to strengthen corporate governance. The company reported a steady financial performance for the half-year ended September 30, 2025, with revenue from operations reaching ₹2,109.25 Lacs, up from ₹1,867.05 Lacs in the previous year. Net profit for the same period increased to ₹620.10 Lacs compared to ₹563.13 Lacs YoY. Additionally, the board ratified previous meeting outcomes that were delayed in submission to the exchanges.
Key Highlights
Revenue from operations grew by 13% YoY to ₹2,109.25 Lacs for the half-year ended September 30, 2025.
Profit After Tax (PAT) for H1 FY26 stood at ₹620.10 Lacs, a growth from ₹563.13 Lacs in H1 FY25.
Total Assets increased significantly to ₹6,694.02 Lacs as of September 2025 from ₹4,907.23 Lacs in March 2025.
Appointment of new Internal and Secretarial Auditors with 7 and 5 years of professional experience respectively.
Current borrowings rose sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025, indicating potential expansion or working capital needs.
👀 What to Watch
Investors should monitor the company's ability to maintain margins given the rise in current borrowings and other expenses. The steady growth in PAT and strengthening of the audit team are positive signs for long-term governance.
GKSL Appoints New Auditors and Reports H1 FY26 PAT of ₹6.20 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has appointed new Secretarial and Internal Auditors for the 2025-26 financial year. The company also resubmitted its financial results for the half-year ended September 30, 2025, to correct typographical errors. These results show a revenue of ₹2,109.25 Lacs and a Profit After Tax (PAT) of ₹620.10 Lacs, compared to a PAT of ₹563.13 Lacs in the previous year's corresponding period. Total assets have grown significantly to ₹6,694.02 Lacs from ₹4,907.23 Lacs in March 2025.
Key Highlights
Revenue from operations for H1 FY26 reached ₹2,109.25 Lacs, up from ₹1,867.05 Lacs in H1 FY25.
Profit After Tax (PAT) for H1 FY26 stood at ₹620.10 Lacs with an EPS of ₹1.22.
Appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26.
Total assets increased to ₹6,694.02 Lacs as of September 30, 2025, compared to ₹4,907.23 Lacs as of March 31, 2025.
The board ratified actions from a previous February meeting that were not initially submitted to stock exchanges.
👀 What to Watch
Investors should monitor the company's administrative compliance given the resubmission of filings, though the underlying financial growth in revenue and profit remains a positive indicator.
GKSL Fined ₹3.30 Lakh by NSE and BSE for Delayed Q2 FY26 Financial Results
Gujarat Kidney And Super Speciality Limited (GKSL) has been penalized by both the National Stock Exchange (NSE) and BSE for non-compliance with SEBI Regulation 33. The exchanges have imposed a fine of ₹3,30,400 due to the company's failure to submit its financial results for the quarter ended September 30, 2025, within the prescribed timeline. While the company claims no significant impact on operations, the delay in reporting is a governance concern. The Board of Directors is expected to review the notice and provide further comments to the exchanges shortly.
Key Highlights
NSE and BSE imposed a total fine of ₹3,30,400 including GST for regulatory non-compliance.
The penalty pertains to the non-submission of financial results for the quarter ended September 30, 2025.
Notices from both exchanges were received by the company on March 17, 2026.
The company stated that the fine does not have a quantifiable impact on its financial or operational activities.
The Board of Directors will shortly review the matter and provide official comments to the stock exchanges.
👀 What to Watch
Investors should exercise caution as delays in financial reporting can indicate internal administrative issues or poor corporate governance. Monitor the company's upcoming board comments to understand the reason behind the reporting delay.
GKSL Reports Q2 FY26 PAT of ₹2.30 Cr; Explains Delay in Financial Result Submission
Gujarat Kidney And Super Speciality Limited (GKSL) has released its delayed financial results for the quarter ended September 30, 2025, citing technical issues following its listing on December 30, 2025. For the quarter, the company reported revenue of ₹9.64 crore and a Profit After Tax (PAT) of ₹2.30 crore. On a half-yearly basis, revenue grew to ₹21.09 crore compared to ₹18.67 crore in the previous year, with PAT increasing to ₹6.20 crore from ₹5.63 crore. The company clarified that this was a first-time oversight due to being a newly listed entity.
Key Highlights
Revenue from operations for Q2 FY26 stood at ₹964.26 Lacs, compared to ₹941.00 Lacs in the same period last year.
Net Profit for the half-year ended September 30, 2025, rose to ₹620.10 Lacs from ₹563.13 Lacs YoY.
Total Assets as of September 30, 2025, increased significantly to ₹6,694.02 Lacs from ₹4,907.23 Lacs in March 2025.
Earnings Per Share (EPS) for the half-year ended September 2025 was reported at ₹1.22.
The reporting delay was attributed to technical issues and the company's recent listing status as of December 30, 2025.
👀 What to Watch
Investors should monitor the company's future compliance to ensure timely disclosures, while noting the steady growth in half-yearly profitability. The current delay appears to be an administrative lapse rather than a fundamental business issue.
Kalyani Steels Settles SEBI Allegations for ₹2.80 Crore; CS Pays ₹95.55 Lakh
Kalyani Steels Limited and its Company Secretary have settled alleged regulatory violations with SEBI by paying a combined amount of approximately ₹3.76 crore. The allegations involved non-compliance with Related Party Transaction (RPT) approvals and disclosure norms under the SEBI LODR Regulations and SCRA. Specifically, the company paid ₹28,022,150, while the Company Secretary paid ₹9,555,000 to close the proceedings. This settlement allows the company to resolve historical compliance issues without admitting or denying the findings, ensuring no further legal overhang on these specific matters.
Key Highlights
Kalyani Steels Limited paid a settlement amount of ₹2,80,22,150 to SEBI.
Company Secretary Mrs. D.R. Puranik paid a separate settlement of ₹95,55,000.
Allegations included violations of Regulation 23(2) and Clause 49 regarding Related Party Transactions and Audit Committee approvals.
The settlement order (SO/JS/DP2025-26/7871-7873) was officially received on February 23, 2026.
The company stated there are no further financial or operational implications beyond the paid amounts.
👀 What to Watch
Investors should view this as a positive step in resolving past regulatory uncertainties, though it highlights previous lapses in governance. The financial impact is manageable and does not affect the core business operations.
GKSL Reports Zero Deviation in Utilization of ₹250.80 Crore IPO Proceeds
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that the ₹250.80 crore raised via equity issuance is being handled as per the original objects. The funds were raised on December 24, 2025, and as of the quarter-end, no deviations or variations in utilization were reported. Major allocations include ₹77 crore for the acquisition of Parekhs Hospital and ₹30.10 crore for a new women's hospital in Vadodara. Brickwork Ratings India Private Limited is acting as the monitoring agency for these funds.
Key Highlights
Raised a total of ₹250.80 crore through an equity share issue on December 24, 2025.
Reported zero deviation or variation in the use of proceeds for the third quarter of FY26.
Allocated ₹77 crore for the acquisition of Parekhs Hospital Private Limited at Ahmedabad.
Earmarked ₹30.10 crore for capital expenditure for a new women's healthcare hospital in Vadodara.
Allocated ₹87.44 crore for inorganic growth through unidentified acquisitions and general corporate purposes.
👀 What to Watch
Investors should track subsequent quarterly reports to ensure the timely and efficient deployment of funds into the stated acquisition and expansion projects. The successful execution of these capital-intensive projects will be a key driver for the company's long-term growth.
GKSL Receives NCLT Approval for Voluntary Revision of Financials and Board Reports (FY22-FY24)
Gujarat Kidney and Super Speciality Limited (GKSL) has received NCLT approval to voluntarily revise its Board Reports and Financial Statements for three financial years (FY22, FY23, and FY24). The revisions primarily address clerical errors, such as incorrect board meeting dates and director appointment timelines. Crucially, the company is correcting a miscategorization in FY24 where a business transfer amount was wrongly labeled as a 'Loan to directors.' Management has confirmed that these revisions have no impact on the company's financial performance, operations, or other activities.
Key Highlights
NCLT Ahmedabad approved the voluntary revision of Board Reports and Financial Statements for FY 2021-22, 2022-23, and 2023-24.
Correction of a miscategorized 'Loan to directors' in FY24 notes, which was actually related to a Business Transfer Agreement.
Rectification of clerical errors regarding the company's conversion date from Private to Public (corrected to 24/11/2023).
The company is directed to pay a nominal fee of ₹10,000 and file revised Form AOC-4 within 30 days.
Management and auditors state there is no quantifiable monetary impact on the company's financial or operational status.
👀 What to Watch
Investors should view this as a corrective governance measure to ensure regulatory accuracy; no immediate action is required as the financials remain fundamentally unchanged. Monitor the filing of the revised reports to confirm the 'Loan to directors' miscategorization is officially resolved.
GKSL Q3 FY26 Standalone PAT Grows 5.4% YoY to ₹2.33 Cr; Revenue Up 14.8%
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady performance for the quarter ended December 31, 2025, with standalone revenue from operations rising 14.8% YoY to ₹976.45 Lacs. Net profit for the quarter saw a modest increase to ₹233.26 Lacs from ₹221.20 Lacs in the previous year. For the nine-month period, the company achieved a PAT of ₹853.36 Lacs, representing an 8.8% growth compared to the same period last year. However, bottom-line growth was slightly constrained by a significant jump in finance costs and other operating expenses.
Key Highlights
Standalone Revenue from Operations increased to ₹976.45 Lacs in Q3 FY26 from ₹850.64 Lacs in Q3 FY25.
Standalone Profit After Tax (PAT) for the quarter stood at ₹233.26 Lacs, up 5.4% year-on-year.
Nine-month (9M FY26) Standalone PAT reached ₹853.36 Lacs compared to ₹784.42 Lacs in 9M FY25.
Finance costs for the quarter rose sharply to ₹29.22 Lacs from ₹10.68 Lacs in the corresponding quarter last year.
The Board approved consolidated results including subsidiaries Raj Palmland Hospital and Harmony Medicare.
👀 What to Watch
Investors should note the steady revenue growth in the healthcare segment but remain cautious about rising finance costs which may impact margins. The stock's performance will likely depend on the successful integration and contribution of its newly consolidated hospital subsidiaries.
GKSL to Acquire 51% Stake in Patel Pharmacy and Patel Multispeciality Hospital for ₹12.50 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the acquisition of a 51% controlling stake in two entities: Patel Pharmacy and Patel Multispeciality Hospital and ICU. The total cash consideration for these acquisitions is approximately ₹12.50 crore, with ₹3.70 crore allocated for the pharmacy and ₹8.80 crore for the hospital. Both target entities are based in Ankleshwar, Gujarat, and have been operational since 2015. This strategic move is aimed at consolidating GKSL's position in the healthcare sector and diversifying its service portfolio beyond specialized kidney care.
Key Highlights
Acquisition of 51% stake in Patel Pharmacy for ₹3.70 crore (FY25 turnover: ₹2.57 crore)
Acquisition of 51% stake in Patel Multispeciality Hospital and ICU for ₹8.80 crore (FY25 turnover: ₹6.46 crore)
Total investment of ₹12.50 crore to be completed via cash consideration within approximately 2 months
Strategic expansion into multispeciality healthcare and pharmacy services to diversify business portfolio
Target entities are established firms in Ankleshwar, Gujarat, with a track record dating back to 2015
👀 What to Watch
Investors should view this as a growth-oriented move that diversifies the company's revenue streams. Monitor the integration of these assets and their contribution to consolidated margins in the next few quarters.
Kalyani Steels Bound by Non-Compete Clause in Ferrous Casting Business
Kalyani Steels (KSL) has been identified as an affiliated entity bound by a non-compete restriction following a Shareholders Agreement (SHA) executed on February 2, 2026. The agreement involves Bharat Forge Limited (BFL), its subsidiaries, and PI Opportunities Fund I Scheme II. Under the terms, KSL is restricted from engaging in the ferrous casting business within India, as this segment is reserved for JS Auto Cast Foundry. While KSL can explore international opportunities in this niche, it may only do so if the JS Auto Board first rejects the opportunity.
Key Highlights
KSL is now bound by non-compete and non-solicitation restrictions for ferrous casting in India.
The restriction stems from an SHA signed on February 2, 2026, between BFL Group and an external investor.
Domestic ferrous casting business is now centralized under JS Auto Cast Foundry India Private Limited.
KSL can only pursue international casting opportunities if they are rejected by the JS Auto Board.
The company confirmed there is no impact on its management or control.
👀 What to Watch
Investors should view this as a formalization of business boundaries within the Kalyani Group. No immediate impact on KSL's core specialty steel operations is expected, though it limits future diversification into domestic casting.
Kalyani Steels Q3 FY26 PAT Rises 10.7% YoY to ₹61.3 Cr Despite Revenue Dip
Kalyani Steels reported a standalone Profit After Tax (PAT) of ₹613.18 million for the quarter ended December 31, 2025, marking a 10.7% increase from ₹553.89 million in the corresponding quarter last year. Revenue from operations declined by 4.5% YoY to ₹4,623.76 million, though it showed a marginal sequential growth from Q2 FY26. The company's bottom line was supported by a significant reduction in total expenses, which fell by 8.3% YoY. Results were slightly impacted by a one-time exceptional charge of ₹67.34 million related to the consolidation of new Labour Codes by the Government of India.
Key Highlights
Standalone PAT grew 10.7% YoY to ₹613.18 million in Q3 FY26.
Revenue from operations decreased 4.5% YoY to ₹4,623.76 million from ₹4,840.05 million.
Total expenses reduced significantly to ₹3,870.13 million from ₹4,219.18 million in the previous year's quarter.
Exceptional one-time expense of ₹67.34 million recognized for incremental impact of new Labour Codes.
Consolidated Earnings Per Share (EPS) for the quarter stood at ₹14.19, up from ₹12.93 YoY.
👀 What to Watch
Investors should focus on the company's ability to expand margins through cost control despite a slight contraction in top-line revenue. The stock remains a solid hold for those looking at the specialty steel segment, with a focus on how volume growth recovers in future quarters.
Kalyani Steels Re-appoints R.K. Goyal as Managing Director for 5-Year Term
Kalyani Steels has confirmed the commencement of Mr. R.K. Goyal's fourth term as Managing Director, effective from January 17, 2026. The reappointment, which spans five years until January 16, 2031, was previously approved by shareholders at the 52nd AGM in August 2025. Mr. Goyal has led the company since 2011 and brings over 42 years of experience in the specialty steel and mining industries. His leadership is notably focused on sustainability, including the development of India's first green steel brands.
Key Highlights
Mr. R.K. Goyal re-appointed as Managing Director for a 5-year term starting January 17, 2026.
The appointee has over 42 years of industry experience and has served as KSL's MD since 2011.
Shareholders previously ratified this fourth term during the 52nd AGM held on August 22, 2025.
Leadership focus remains on green steel initiatives and reducing GHG emission intensity.
Confirmation provided that the appointee is not debarred from holding office by SEBI or any authority.
👀 What to Watch
Investors should view this as a positive sign of leadership continuity and stability for the company's long-term strategy. No immediate action is required as this is a scheduled continuation of existing management.
